NKGEN BIOTECH INC (NKGN) Stock Income Statement
USA - NASDAQ:NKGN - US65488A1016 - Common Stock
0.1913 USD
-0.32 (-62.91%)
0.19 USD
0 (-0.68%)
| TTM (2024-6-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | 0 | null | null | null | |||
| Gross Profit | null | 0 | null | null | null | |||
| Operating Expenses | 31.41M | 29.75M | 2.74M | 2.51M | null | |||
| Research and Development | 14.34M | 15.67M | null | null | null | |||
| Selling, General, and Administrative Expenses | 17.07M | 14.08M | 2.74M | 2.51M | null | |||
| Operating Income | -31.41M | -29.75M | -2.74M | -2.51M | 0 | |||
| Interest Income/Expense | -65.15M | -48.95M | 7.55M | 5.71M | null | |||
| Other Income/Expense | 1.72M | 120.00K | 180.00K | -4.19M | null | |||
| Non Recurring Items | 6.59M | -4.37M | null | null | null | |||
| Income Before Taxes | -88.25M | -82.95M | 4.99M | -990.00K | null | |||
| Income Tax | null | 7.00K | 440.00K | null | null | |||
| Net Income | -88.26M | -82.95M | 4.55M | -990.00K | null | |||
| EBITDA | -29.62M | -28.54M | undefined | undefined | undefined | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -4.706099999999999 | -3.6374 | 0.21 | -0.07 | null | |||
| Non GAAP EPS | null | null | null | null | null | |||
| Statistics | ||||||||
All data in USD